Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 29, Issue 8, Pages 1272-1276Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2015.08.023
Keywords
Microbiota; beta-Glucan; Inulin; Blueberry; Glucose tolerance; Satiety
Categories
Funding
- Microbiome Therapeutics LLC
- NORC Center Grant [2P30DK072476]
- NIDDK
- National Institute of General Medical Sciences of the National Institutes of Health the Louisiana Clinical and Translational Science Center [1 U54 GM104940]
Ask authors/readers for more resources
Objective: The objective of this study was to examine the effects of a gastrointestinal microbiome modulator (GIMM) containing inulin, beta-glucan, blueberry anthocyanins, and blueberry polyphenols on metabolic parameters, fecal markers of gut microbiota, and satiety. Design and methods: Thirty overweight or obese individuals aged 18 to 70 years, were enrolled in a randomized controlled trial. Participants consumed the test product or placebo daily for four weeks. Stool samples were collected and blood was drawn at baseline and week four for assessments of gut microbiota, satiety hormones, glucose control, and lipid measures. Subjective satiety was assessed weekly. Linear models were used to compare differences from baseline to week four. Results: GIMM consumption improved blood glucose tolerance (p = 0.008), and increased satiety (p = 0.03). There were no statistically significant differences in insulin sensitivity, fecal markers of gut microbiota, plasma satiety hormones, or serum lipid concentrations between the groups. However, plasma satiety hormones and fecal short chain fatty acid concentrations increased in the test group compared to the placebo. Conclusions: GIMM consumption for four weeks, increases satiety, and improves glucose tolerance possibly through insulin-independent pathways. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available